|
|

Link:
Pharm/Biotech Resources
Title: Skin and mucosal treatment formulation
United States Patent: 6,949,262
Issued: September 27, 2005
Inventors: Smothers; Don L. (Dallas, TX)
Assignee: LouSal Enterprises, Inc. (Aledo, TX)
Appl. No.: 445794
Filed: May 27, 2003
Abstract
A treatment composition for use in providing relief of dryness of the
nasal tissues and other dry skin, and particularly to providing such relief
without the use of petroleum products.
SUMMARY OF THE INVENTION
The present invention is directed to providing relief of dryness of the
nasal tissues and other dry skin, and particularly to providing such relief
over an extended period of time and without the use of petroleum products.
More particularly, the present invention is directed to a skin and mucosal
treatment composition that is applied to mucosa (such as nasal tissue) or to
the skin (such as facial areas exposed to an oxygen mask) and remains in
place for a substantial period of time, and which can release moisture to
the nasal tissues or treated skin and also forms a barrier on the exposed
area to protect it from the drying and chafing activity caused by dry
climates, continuous oxygen flow, or oxygen-delivery equipment. By doing so,
the user is more comfortable and the nasal tissues and other exposed skin
are healthier, without reliance on petroleum products.
The present invention provides a skin and mucosal composition comprising:
aloe, dimethicone, allantoin, and water in a carrier base such as an oil, a
cream, or a gel.
DETAILED DESCRIPTION OF THE INVENTION
As used herein and in the accompanying claims, the terms "a" and "an"
mean "one or more", unless otherwise indicated.
The components of the petroleum-free skin and mucosal treatment composition
of the present invention are chosen to be safe for use on the nasal tissues
and to be non-irritating.
Useful formulations of the skin and mucosal composition comprise aloe in an
amount ranging from about 35 wt % to about 80 wt %, dimethicone in an amount
ranging from about 1 wt % to about 3 wt %, allantoin in an amount ranging
from about 0.5 wt % to about 3 wt %, and water in an amount ranging from
about 20 wt % to about 40 wt %. One presently preferred formulation of the
invention comprises about 50 wt % aloe vera, about 2 wt % dimethicone, about
0.6 wt % allantoin, about 35 wt % water, and about 12.4 wt % other
ingredients.
Other ingredients or components may be included in the skin and mucosal
composition of the invention. Such other components may be selected from,
but are not limited to: humectants, preservatives, emollients, buffers,
coloring agents, fragrances, solubilizing agents, stabilizing agents,
gel-forming agents, oils, antibiotics, herbal materials, and vitamins. Each
of these ingredients can be present in any amount that does not
substantially interfere with the skin-protecting and skin-moisturizing
functions of the treatment composition.
The hydrating skin and mucosal compositions of the present invention are
effective at a viscosity preferably ranging from between about 5,000
centipoise to about
300,000 centipoise at room temperature (RT), or about 25° C. Preferably, the
viscosity of the composition of the invention is between about 20,000 and
about 100,000 centipoise at RT, and more preferably between about 25,000 and
60,000 centipoise.
To treat dry skin or mucosa, the skin and mucosal treatment composition of
the invention is administered to the area(s) of the skin or mucosa that
exhibit discomfort, soreness, cracking, bleeding, chafing, irritation, or
other symptoms of dryness. The treatment composition is applied in an amount
and at time intervals as necessary to provide relief from such symptoms. For
example, for oxygen users, the composition can be applied at any time during
oxygen therapy in sufficient amounts to both the internal and external
membranes of the nasal passage, as well as over the ear to reduce friction
created by cannula rubbing. CPAP users can apply the treatment composition
to the facial area where the oxygen mask meets and covers the skin before
beginning therapy. The treatment composition of the invention will not leave
a sticky residue on the skin.
The following example further illustrates the invention. However, the
invention is not limited thereto, and it will be apparent to those of
ordinary skill in the art from the teachings herein that equivalent
modifications thereof may be made without departing from the spirit and
scope of this invention.
EXAMPLE 1
A skin and mucosal composition was prepared according to the formula shown
in Table I.
| TABLE I |
| Ingredient |
Weight % |
| Aloe Vera |
50.000 |
| Water |
34.886 |
| Glycerine 99.5% USP |
4.000 |
| Rice Bran Oil |
2.000 |
| Emu Oil |
2.000 |
| Dimethicone |
2.000 |
| DEA oleth-3 phosphate1 |
2.000 |
| Carbopol 940 |
1.000 |
| Triethanolamine 99% |
0.600 |
| Allantoin |
0.600 |
| Undebenzophene-C |
0.500 |
| Sodium hydroxymethylglycinate2 |
0.200 |
| Tocopherol Acetate |
0.100 |
| d-L Panthenol |
0.100 |
| Fragrance - Baby Powder |
0.010 |
| Vitamin A Acetate |
0.004 |
| 1Crodofos ® N3 Neutral, Croda, Parsippany, NJ |
| 2Suttocide-A ®, Van Wagoner and Associates, Highland
Village, TX |
PHASE-1
The water and glycerin were mixed together, after which Carbopol was added
and dispersed into the mixture with high shear until completely smooth with
no lumps. The mixture was then heated to 65° C.
PHASE-2
The emu oil, undebenzophene, DEA oleth-3 phosphate, vitamin A acetate,
dimethicone and rice bran oil were mixed together and heated to 65° C.
PHASE-3
The aloe vera, Suttocide A, allantoin, panthenol and tocopherol acetate were
added together and agitated until completely dissolved.
When the heated phases reached the specified temperatures, PHASE 2 was added
to PHASE 1 until the emulsion was smooth and free of lumps. PHASE 3 was then
added to the emulsion with high shear until homogeneous. Cooling of the
resulting mixture was begun, with continued regular agitation, and
triethanolamine was added. When the batch reaches 30° C., the fragrance was
added, with continued agitation, and the pH was adjusted to 5.6±0.3. The
final product had the following specifications:
| Color |
white to off-white |
| Odor |
light fragrance |
| Appearance |
soft cream |
| Viscosity |
32,000-52,000 cps |
| Specific Gravity |
0.995-1.005 |
| Microbiological Profile: |
| Total Count |
10 cfu/mL max. |
| Pathogenic Bacteria |
none |
| Mold or yeast |
none |
Claim 1 of 11 Claims
1. A skin and mucosal treatment composition comprising of the total amount
of the composition:
Aloe vera in an amount ranging from about 35 weight % to about 80 weight
%,
dimethicone in an amount ranging from about 1.5 weight % to about 3 weight
%,
allantoin in an amount ranging from about 0.5 weight % to about 3 weight
%, and
water in an amount ranging from about 20 weight % to about 40 weight %.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|